Data Sheet 1_Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic NSCLC.docx

Background<p>Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-based combination therapy modalities for patients with EGFR-mutated stage IV non-small cell lung cancer (NSCLC) are being investigated. We evaluated the value and safety of third-generation EGFR-TKIs combined...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	Xinhang Gu (22686224) (author)
Weitere Verfasser:	Jiaxiao Geng (22509188) (author), Hongfu Sun (10054227) (author), Qiang Cao (119096) (author), Yan Yi (504321) (author), Baosheng Li (290758) (author)
Veröffentlicht:	2025
Schlagworte:	Oncology and Carcinogenesis not elsewhere classified non-small cell lung cancer radiotherapy epidermal growth factor receptor tyrosine kinase inhibitor radiation dosage
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!

Data Sheet 1_Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic NSCLC.docx

Ähnliche Einträge